Search results for "PARKINSON'S"

showing 10 items of 232 documents

The Implications Of The Foot Health Status In Parkinson Patients : A Case-Control Study

2022

Parkinson's disease (PD) is a neurodegenerative disorder that affects bothhealth of the feet, as to gait patterns. This study aimed to find out about footproblems and their impact on self-perceived quality of life and related to foothealth in Parkinson's patients compared to a group of healthy subjects and tomeasure it with Spanish Podiatry Health Questionnaire (PHQ-S). It is about acase–control study in a sample of Parkinson's patients n=62, healthy controlsn=62. The PHQ-S was reported, it describes perception the subject has ineach of podiatric 6 dimensions consulted, assessing appreciation of health sta-tus of interviewee's feet and a self-rated the foot health score on the visual ana-lo…

Quality of lifePHQ-SFootHealth StatusParkinson's diseasePiesParkinson DiseaseDermatologyExtremitatsCase-Control StudiesFoot painQuality of LifeHumansSurgerySistema nerviós MalaltiesSpanish podiatry health questionnaireParkinson's diseaseFoot health statusSpanish podiatryhealth questionnaire
researchProduct

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct

Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

2014

N.A.

RasagilineN.A.medicine.medical_specialtyNeurologyParkinson's diseasebusiness.industryDermatologyGeneral Medicinemedicine.diseaseInsidious onsetPsychiatry and Mental healthchemistry.chemical_compoundchemistrymedicineNeurology (clinical)NeurosurgerybusinessPsychiatryNeuroradiology
researchProduct

Reversible Pisa Syndrome in a patient with Parkinson's disease on rasagiline therapy

2013

RasagilinePediatricsmedicine.medical_specialtyParkinson's diseasebusiness.industrymedicine.diseasechemistry.chemical_compoundNeurologychemistryPhysical therapyMedicineNeurology (clinical)businessPisa Syndrome rasagilineJournal of the Neurological Sciences
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

NEUROPROTECTIVE ACTION OF RESVERATROL AGAINST OXIDATIVE STRESS AND IN THE MOUSE MODEL OF PARKINSON'S DISEASE.

2008

Resveratrol neuroprotection oxidative stress parkinson's deseaseSettore BIO/09 - Fisiologia
researchProduct

Buccal delivery as a new challenge for treatment of motor fluctuations in Parkinson's Disease

2011

RopiniroleParkinson's DiseaseApomorphineSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBuccal deliveryL-Dopa methyl ester
researchProduct

Controlled Drug delivery in Parkinson's Disease - Progress beyond the state-of-the-art

2009

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoControlled delivery Parkinson's Disease
researchProduct

The Home-based Empowered Living for Parkinson's disease patients

2009

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoIntelliDrug Parkinson's disease
researchProduct

Implications for Estrogens in Parkinson’s Disease

2006

Evidence from experimental and epidemiological studies suggests a role of sex hormones in the pathogenic process leading to neurodegenerative diseases, (i.e., Alzheimer's and Parkinson's disease). The effects of sexual steroid hormones are complex and vary with the events of women's fertile life. Estrogens are supposed to influence dopamine synthesis, metabolism, and transport; however, there is no consensus regarding the direction, locus, and mechanism of the effect of estrogens on the dopaminergic system. A neuroprotective effect of estrogens has been demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-animal models of Parkinson's disease (PD). Epidemiological studies indi…

Settore MED/26 - NeurologiaAge at menopause Parkinson's disease
researchProduct